Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 170
Filter
2.
Breast Cancer Res Treat ; 160(1): 101-109, 2016 11.
Article in English | MEDLINE | ID: mdl-27663436

ABSTRACT

PURPOSE: The purpose of this study is to evaluate survival outcome in patients with hormone receptor (HR)-positive (+) metastatic breast cancer (MBC) who received fluoxymesterone after disease progression while receiving contemporary hormonal therapy, as well as the association between estrogen receptor (ER)/androgen receptor (AR) status and survival outcome in these patients. METHODS: We retrospectively identified 103 patients treated with fluoxymesterone for HR + MBC from 2000 to 2014 and with at least one previous hormonal therapy in a metastatic setting. RESULTS: A median of 3 (range 1-10) hormonal therapies (aromatase inhibitors, tamoxifen, and/or fulvestrant) were received before fluoxymesterone; 33 patients discontinued fluoxymesterone before progression because of physician decision or adverse events including toxicity in 14 patients. Of the remaining 70 patients, 2 (3 %) had complete response, 7 (10 %) partial response, and 21 (30 %) stable disease for at least 6 months, yielding a clinical benefit rate of 43 %. The median PFS was 3.9 months (95 % CI 3.2-5.3 months). Multivariate analysis revealed no significant association between PFS and the type or number of prior systemic treatments. All 39 patients who had archived tumor slides available for AR staining had ER + carcinoma; 10 had ≥1 % but <10 %, 18 had ≥10 %, and 11 had no AR nuclear expression. AR positivity with various cutoffs (i.e. any AR + cells, ≥1 % AR + cells, or ≥10 % AR + cells) was not significantly associated with survival outcome. CONCLUSIONS: Fluoxymesterone can be considered for patients whose ER + MBC progresses on contemporary hormonal therapy, regardless of the level of AR expression.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Fluoxymesterone/therapeutic use , Receptors, Androgen/metabolism , Receptors, Estrogen/metabolism , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Breast Neoplasms/diagnosis , Breast Neoplasms/mortality , Drug Resistance, Neoplasm , Female , Follow-Up Studies , Gene Expression , Humans , Kaplan-Meier Estimate , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Proportional Hazards Models , Receptors, Androgen/genetics , Receptors, Estrogen/genetics , Retrospective Studies , Treatment Outcome
5.
Stat Med ; 20(4): 557-79, 2001 Feb 28.
Article in English | MEDLINE | ID: mdl-11223901

ABSTRACT

In this paper we propose formulae for calculating the expected number of events or, alternatively, the required trial duration, for clinical trials involving two treatment groups in which patients may potentially experience multiple events and the data will be analysed using a multiplicative intensity (MI) model. We use a partial likelihood-based approach and examine in detail two MI models: one that includes a binary treatment variable as the only covariate and a three-state Markov process model in which a binary time-varying covariate is added to the previous model. For the simpler model, our formula coincides with those derived by Cook using full likelihood methods. We present applications of the derived formulae to chronic granulomatous disease and breast cancer data sets.


Subject(s)
Models, Biological , Randomized Controlled Trials as Topic/methods , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Child , Cyclophosphamide/therapeutic use , Disease-Free Survival , Female , Fluorouracil/therapeutic use , Fluoxymesterone/therapeutic use , Granulomatous Disease, Chronic/drug therapy , Humans , Interferon-gamma/therapeutic use , Likelihood Functions , Markov Chains , Methotrexate/therapeutic use , Prednisone/therapeutic use , Sample Size , Tamoxifen/therapeutic use
6.
J Clin Oncol ; 17(10): 3299-306, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10506633

ABSTRACT

PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer anorexia/cachexia. PATIENTS AND METHODS: Patients suffering from cancer anorexia/cachexia were randomized to receive either dexamethasone 0. 75 mg qid, megestrol acetate 800 mg orally every day, or fluoxymesterone 10 mg orally bid. Patients were observed at monthly intervals to evaluate weight changes and drug toxicity. Patients also completed questionnaires at baseline and at monthly intervals to evaluate appetite and drug toxicities. RESULTS: Fluoxymesterone resulted in significantly less appetite enhancement and did not have a favorable toxicity profile. Megestrol acetate and dexamethasone caused a similar degree of appetite enhancement and similar changes in nonfluid weight status, with nonsignificant trends favoring megestrol acetate for both of these parameters. Dexamethasone was observed to have more corticosteroid-type toxicity and a higher rate of drug discontinuation because of toxicity and/or patient refusal than megestrol acetate (36% v 25%; P =.03). Megestrol acetate had a higher rate of deep venous thrombosis than dexamethasone (5% v 1%; P =.06). CONCLUSION: Whereas fluoxymesterone clearly seems to be an inferior choice for treating cancer anorexia/cachexia, megestrol acetate and dexamethasone have similar appetite stimulating efficacy but differing toxicity profiles.


Subject(s)
Anabolic Agents/therapeutic use , Anorexia/drug therapy , Antiemetics/therapeutic use , Appetite/drug effects , Cachexia/drug therapy , Dexamethasone/therapeutic use , Fluoxymesterone/therapeutic use , Megestrol Acetate/therapeutic use , Neoplasms/physiopathology , Administration, Oral , Aged , Anabolic Agents/pharmacology , Anorexia/etiology , Body Weight , Cachexia/etiology , Female , Fluoxymesterone/pharmacology , Humans , Male , Middle Aged , Neoplasms/complications , Treatment Outcome , Weight Gain
7.
Harefuah ; 134(3): 178-80, 247, 1998 Feb 01.
Article in Hebrew | MEDLINE | ID: mdl-9662906

ABSTRACT

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder of blood cells which originate from an abnormal hematopoietic stem cell. The condition is characterized by nocturnal hemoglobinuria, chronic hemolytic anemia, and thrombosis. We describe a 60-year-old woman with PNH admitted with abdominal pain and jaundice, who had dark urine on arising after a night's sleep. The diagnosis was established by the typical clinical story and a positive Ham test. She was successfully treated with Halotestin and folic acid. Although PNH is rare, it should be considered in the differential diagnosis of hemolytic anemia. Early diagnosis and treatment are important.


Subject(s)
Hemoglobinuria, Paroxysmal/diagnosis , Diagnosis, Differential , Female , Fluoxymesterone/therapeutic use , Folic Acid/therapeutic use , Hemoglobinuria, Paroxysmal/drug therapy , Hemoglobinuria, Paroxysmal/physiopathology , Humans , Jaundice , Middle Aged , Pain , Sleep
8.
Ann Intern Med ; 121(4): 247-51, 1994 Aug 15.
Article in English | MEDLINE | ID: mdl-7518657

ABSTRACT

OBJECTIVE: To determine the effects of androgen administration on measures of thyroid function and thyroid hormone replacement doses in women with breast cancer. DESIGN: Consecutive patients with metastatic, hormone-dependent breast cancer who were eligible for androgen treatment. INTERVENTIONS: Androgen therapy (fluoxymesterone, 10 mg orally twice daily) was continued for as long as it was effective in controlling tumor growth. PATIENTS: 7 patients with no known thyroid disease and 4 others receiving long-term treatment for hypothyroidism. MEASUREMENTS: Serum levels of total and free thyroxine (T4), thyroid-stimulating hormone (TSH), and T4-binding globulin were determined before and every 4 weeks after androgen therapy was initiated. RESULTS: Within 4 weeks of androgen administration to the seven patients without thyroid disease, serum levels of total T4 and T4-binding globulin decreased (P < 0.001), whereas the calculated free thyroxine index and measured free hormone levels remained unchanged. Six to 12 weeks after androgen therapy was discontinued, all seven patients remained clinically euthyroid, and serum levels returned to baseline values. In contrast, clinical hyperthyroidism developed shortly after androgen was administered to four patients who received long-term thyroid hormone replacement therapy. Within 4 weeks of treatment, the serum free T4 level increased in each of the four patients, whereas the TSH level decreased. Thyroid hormone doses had to be reduced by 25% to 50% to maintain euthyroidism. CONCLUSIONS: The study documents the reversible effects of androgens on thyroid hormone levels and indicates the need to reduce thyroid replacement doses in women during androgen therapy. Monitoring thyroid hormone levels in patients receiving replacement therapy and perhaps in those with autonomous thyroid function is necessary after androgen therapy.


Subject(s)
Breast Neoplasms/drug therapy , Fluoxymesterone/pharmacology , Hypothyroidism/drug therapy , Thyroxine/administration & dosage , Aged , Breast Neoplasms/blood , Breast Neoplasms/complications , Female , Fluoxymesterone/therapeutic use , Humans , Hypothyroidism/blood , Hypothyroidism/complications , Middle Aged , Palliative Care , Thyrotropin/drug effects , Thyroxine/blood , Thyroxine/drug effects , Thyroxine/therapeutic use , Thyroxine-Binding Proteins/drug effects
9.
Br J Haematol ; 87(1): 205-8, 1994 May.
Article in English | MEDLINE | ID: mdl-7947249

ABSTRACT

Twenty patients with myelodysplastic syndromes (MDS) and (i) platelets < 50 x 10(9)/l and (ii) bone marrow blasts < or = 10% were treated with androgen therapy (fluoxymesterone at 1 mg/kg/d: seven patients; danazol at 600 mg/d: 13 patients) for at least 3 months. 11 of them (55%) had an increase in platelet counts by at least 30 x 10(9)/l and a disappearance of bleeding symptoms was seen in 6/6 patients with initial bleeding. A response with neutrophil counts (six cases) or haemoglobin levels (five cases) was less often seen. Treatment was continued for 3+ to 27 months in responders (the dose being reduced by 50% after 6 months). Seven patients on maintenance treatment were still responding. Another patient died while he was still responding, and the remaining three patients relapsed after discontinuation (two cases) and dose reduction to 50% (one case) of the androgen used. Side-effects of treatment were moderate. In our experience, androgen therapy can be useful in patients with 'low risks' MDS (i.e. with marrow blasts < or = 10%) and severe thrombocytopenia, especially because no growth factor regularly active on platelets is currently available.


Subject(s)
Danazol/therapeutic use , Fluoxymesterone/therapeutic use , Myelodysplastic Syndromes/complications , Thrombocytopenia/drug therapy , Adult , Aged , Aged, 80 and over , Female , Hemoglobins/analysis , Humans , Leukocyte Count/drug effects , Male , Middle Aged , Neutrophils/drug effects , Pilot Projects , Platelet Count/drug effects , Thrombocytopenia/etiology
10.
Presse Med ; 22(23): 1079-86, 1993 Jun 26.
Article in French | MEDLINE | ID: mdl-8415459

ABSTRACT

Fifty cases of chronic pure red cell aplasia in adults (idiopathic in 32 cases, associated with chronic lymphocytic leukaemia in 18) were followed up after studying their erythroblastic precursors in vitro. Analysis of response to immunomodulators confirmed the existence, in patients with idiopathic chronic pure red cell aplasia, of a relationship between in vitro behaviour and obtention of a remission: patients with normal differentiation of erythroblasts consistently responded to treatments, whereas treatments were usually ineffective when the erythroblasts did not differentiate in vitro. When in vitro differentiation was below normal, responses to treatments were varied. In patients with chronic lymphocytic leukaemia, the erythroblastic precursors were normal in 15/18 cases, and response to immunomodulators was observed in 13/18 cases. A second objective of this study was to determine, on a large series, the most adequate immunomodulator treatment. In idiopathic chronic pure red cell aplasia the most efficient therapy was corticosteroids and cyclophosphamide administered separately or together. The antilymphocyte serum gave disappointing results. In pure red cell aplasia associated with leukaemia cyclophosphamide was the most frequently effective drug, with corticosteroids taking second rank; however, infections were frequent. The treatments to be considered when both corticosteroids and cyclophosphamide fail are discussed.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Cyclophosphamide/therapeutic use , Cyclosporine/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Red-Cell Aplasia, Pure/drug therapy , Adult , Antilymphocyte Serum/therapeutic use , Azathioprine/therapeutic use , Cells, Cultured , Chronic Disease , Drug Therapy, Combination , Erythroid Precursor Cells , Fluoxymesterone/therapeutic use , Humans , Immunoglobulins, Intravenous/therapeutic use , Red-Cell Aplasia, Pure/etiology , Remission Induction
11.
Pediatrics ; 91(4): 716-20, 1993 Apr.
Article in English | MEDLINE | ID: mdl-8464656

ABSTRACT

This prospective study was designed to assess growth response, side effects, other possible long-term effects, and final adult height in boys treated with the oral androgen, fluoxymesterone. From 1973 to 1984, eighty-two short boys (71 with constitutional delay of growth and puberty [CDGP] and 11 with genetic short stature [GSS]) were treated with daily oral doses of 2.5 mg of fluoxymesterone from 6 to 60 months. Final height assessment was made from 1989 to 1991. A group of 34 untreated boys (26 with CDGP and 8 with GSS) were also followed to assess the accuracy of the Greulich-Pyle and Bayley-Pinneau (GP-BP) and sexual maturity index height prediction methods. During treatment, each patient had a 1.7- to 2.5-fold increase in linear growth velocity. Accelerated velocity (over baseline) continued as long as the bone age was less than 14 years. No adverse androgenic effects (or undue acceleration of puberty) were observed. Final height exceeded pretreatment predictions for CDGP + GSS by 6.1 +/- 3.5 (SD) cm (GP-BP) and 5.4 +/- 3.2 cm (sexual maturity index). It is concluded that a daily oral dose of 2.5 mg of fluoxymesterone can be used to accelerate linear growth in boys with CDGP and GSS when needed to alleviate emotional problems secondary to slow growth and short stature without fear of compromising final adult height.


Subject(s)
Fluoxymesterone/therapeutic use , Growth Disorders/drug therapy , Adolescent , Body Height/drug effects , Child , Fluoxymesterone/administration & dosage , Fluoxymesterone/pharmacology , Growth Disorders/genetics , Humans , Male , Prospective Studies , Puberty, Delayed/drug therapy , Reference Values , Time Factors , Treatment Outcome
12.
Auris Nasus Larynx ; 20(2): 131-5, 1993.
Article in English | MEDLINE | ID: mdl-8216048

ABSTRACT

Five cases of juvenile nasopharyngeal angiofibroma were studied in terms of the presence of progesterone, estradiol, testosterone, and dihydrotestosterone in the juvenile nasopharyngeal angiofibroma tissue using the peroxidase-antiperoxidase method. Progesterone and estradiol were positive in all cases. Testosterone was positive in 2 of the 5 patients. Dihydrotestosterone was positive in 3 of the 5 patients. Hormone in the juvenile nasopharyngeal angiofibroma tissue seems to change by the activity of nasopharyngeal angiofibroma.


Subject(s)
Angiofibroma/pathology , Nasopharyngeal Neoplasms/pathology , Adolescent , Adult , Angiofibroma/drug therapy , Angiofibroma/surgery , Fibroblasts/drug effects , Fibroblasts/ultrastructure , Fluoxymesterone/administration & dosage , Fluoxymesterone/therapeutic use , Flutamide/administration & dosage , Flutamide/therapeutic use , Gonadal Steroid Hormones/therapeutic use , Humans , Male , Neoplasm Staging , Photomicrography , Sex Factors
13.
Horm Res ; 39 Suppl 2: 3-6, 1993.
Article in English | MEDLINE | ID: mdl-8395455

ABSTRACT

The aims of this national multicentre study in Finland were to evaluate whether the height velocity of patients with Turner syndrome would increase with the conventional human growth hormone (GH) therapy regimen normally given to GH-deficient children and whether girls with Turner syndrome actually show GH neurosecretory dysfunction. Finally, the study should show whether GH therapy improves height prognosis and, eventually, final height. Twenty-five girls with Turner syndrome, aged 7.5-14.4 years, entered the study. Their ability to secrete GH was determined and, surprisingly, several would have been classified as having GH deficiency. All girls received GH, 0.1 IU/kg/day (maximum dose 4 IU/day) s.c., and once over 12.5 years old, they also received oestradiol valerate and fluoxymesterone. They showed a convincing increase in height velocity, and rapid growth continued during the second year of therapy. The effect of GH therapy on final height is still unknown. The therapy was remarkably free of side-effects.


Subject(s)
Body Height/drug effects , Growth Hormone/therapeutic use , Growth/drug effects , Turner Syndrome/drug therapy , Adolescent , Bone Development/drug effects , Child , Estradiol/analogs & derivatives , Estradiol/therapeutic use , Estrogens, Conjugated (USP)/therapeutic use , Female , Finland , Fluoxymesterone/therapeutic use , Follow-Up Studies , Growth Hormone/metabolism , Growth Hormone/pharmacology , Humans , Pituitary Gland/drug effects , Pituitary Gland/metabolism , Prognosis , Turner Syndrome/blood , Turner Syndrome/physiopathology
14.
Am J Clin Oncol ; 15(3): 233-5, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1590276

ABSTRACT

The Piedmont Oncology Association conducted a Phase II trial of fluoxymesterone (Halotestin) in 28 patients who failed to respond to prior hormonal therapy with tamoxifen and a progestational agent. Of nine patients who had responded to prior endocrine therapy, one had a partial response (PR) as defined by strict criteria and remains on study at 17 + months for an 11% response rate [95% confidence interval (CI), complete response (CR) + PR, 0-48%]. None of 19 previously unresponsive patients achieved remission (95% CI, CR + PR, 0-18%). Eleven patients' performance status deteriorated during therapy. Five of them had not received prior chemotherapy, and their response to subsequent chemotherapy may have been adversely affected. Third-line hormonal therapy with fluoxymesterone can be recommended only as a temporizing measure in patients with indolent disease who have responded to prior hormonal therapy.


Subject(s)
Breast Neoplasms/drug therapy , Fluoxymesterone/therapeutic use , Adult , Aged , Aged, 80 and over , Drug Evaluation , Female , Humans , Middle Aged
15.
Cancer ; 69(1): 213-8, 1992 Jan 01.
Article in English | MEDLINE | ID: mdl-1727665

ABSTRACT

Fifteen patients with previously untreated metastatic prostate cancer were treated on a pilot trial with a combination of maximal androgen blockade plus intermittent cytotoxic therapy after androgen priming to stimulate cell division. Androgen blockage was carried out using a gonadotropin-releasing hormone analog (leuprolide) plus a nonsteroidal antiandrogen (flutamide). Carboplatin (CBDCA) (800 mg/m2) was given intravenously every 28 days, preceded for 3 days and followed for 3 days by androgen treatment with fluoxymesterone (5 mg orally twice a day), during which time flutamide was discontinued. Three patients (20%) achieved a complete response (CR), and eight patients (53.3%) achieved a partial response (PR). Four patients (26.7%) had stable disease (SD). The median progression-free survival (PFS) time was 31 months. Nine of 15 patients (60%) remain alive with a median follow-up time of 42+ months (range, 22 to 54 months). Grade 4 thrombocytopenia and Grades 3 or 4 leukopenia were experienced in 87% and 80% of patients, respectively, requiring dose reductions of CBDCA in 85% of the cycles. Six of 15 patients experienced a flare in bone pain with androgen priming. There were no associated spinal cord compressions; however, exclusion of impending spinal cord compression was required before entrance on study.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/secondary , Androgens/physiology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasms, Hormone-Dependent/drug therapy , Prostatic Neoplasms/drug therapy , Aged , Carboplatin/administration & dosage , Drug Evaluation , Fluoxymesterone/therapeutic use , Flutamide/therapeutic use , Humans , Leuprolide/administration & dosage , Male , Middle Aged , Pilot Projects , Remission Induction , Survival Analysis
16.
Int J Hematol ; 54(2): 103-7, 1991 Apr.
Article in English | MEDLINE | ID: mdl-1747444

ABSTRACT

We retrospectively evaluated the efficacy of androgen in the treatment of refractory anemia (RA) and compared patient characteristics and the probability of survival in androgen-responder and nonresponder groups. Forty patients with RA were treated in our hospital between 1975-1989, and 27 were treated with various derivatives of androgen. Eleven of the latter responded effectively to androgen therapy, representing an efficacy rate of 40.7%, higher than that of any other treatments thus far reported. The probability of 10-year survival estimated by the Kaplan-Meier method was 75.0% for the responder group and 41.3% for nonresponders, with a median follow-up of 1202 and 1272 days, respectively. In addition, the percent probability of transformation-free survival was higher among androgen-responders than among nonresponders, though the difference was not significant. Transformation from RA to RAEB or overt leukemia was seen in only one case among the former group, but in six among the latter. With respect to patient characteristics, only the percentage of marrow myeloblasts differed significantly between the groups.


Subject(s)
Androstanols/therapeutic use , Anemia, Refractory/drug therapy , Danazol/therapeutic use , Fluoxymesterone/therapeutic use , Methenolone/analogs & derivatives , Adolescent , Adult , Aged , Aged, 80 and over , Anemia, Refractory/mortality , Drug Evaluation , Follow-Up Studies , Humans , Life Tables , Methenolone/therapeutic use , Middle Aged , Retrospective Studies
18.
Cancer ; 67(4): 886-91, 1991 Feb 15.
Article in English | MEDLINE | ID: mdl-1991261

ABSTRACT

A randomized trial was performed to determine if therapy with tamoxifen (TAM) plus fluoxymesterone (FLU) was more efficacious than TAM alone for postmenopausal women with metastatic breast cancer. Patients failing TAM could subsequently receive FLU. The dose of both drugs was 10 mg orally twice daily. Objective responses were seen in 50 of 119 (42%) TAM patients and 64 of 119 (54%) TAM plus FLU patients (two-sided P = 0.07). Time to disease progression was better for TAM plus FLU (medians: 11.6 versus 6.5 months; Cox model, P = 0.03). Duration of response and survival were similar in the two treatment arms. Among 97 patients with estrogen receptor (ER) of 10 or greater and 65 years of age or older, there were highly significant advantages for treatment with TAM plus FLU in both response rate and time to progression. Of particular note is that in this patient group TAM plus FLU showed a survival advantage (Cox model, P = 0.05). Although these data require confirmation in a prospective randomized trial, they suggest that there is a substantive therapeutic advantage for TAM plus FLU over TAM alone in elderly women with ER of 10 fmol or greater.


Subject(s)
Breast Neoplasms/drug therapy , Fluoxymesterone/therapeutic use , Menopause , Tamoxifen/therapeutic use , Adult , Aged , Aged, 80 and over , Breast Neoplasms/mortality , Drug Evaluation , Female , Fluoxymesterone/administration & dosage , Humans , Middle Aged , Receptors, Estrogen/analysis , Remission Induction , Survival Rate , Tamoxifen/adverse effects , Weight Gain/drug effects
20.
Cancer Res ; 51(2): 624-8, 1991 Jan 15.
Article in English | MEDLINE | ID: mdl-1985778

ABSTRACT

Seventy-two patients with advanced breast carcinoma (42% bone, 25% visceral, 5.5% soft tissue, and 27.5% multiple site metastases) were evaluated to determine the relationship between tumor expression of the estrogen-regulated protein pS2, estrogen receptor (ER) or progesterone receptor (PgR) content, and response to hormonal therapy. Twenty-nine % of tumors were pS2 positive, 64% were ER positive, and 29% were PgR positive. Of the ER-positive patients (n = 43), 15 (35%) had greater than 10% of the invasive carcinoma which immunostained for pS2 (these were considered pS2 positive). Only 3 of 24 ER-negative tumors were pS2 positive. A weak association between pS2 expression and ER content (P = 0.08) but not PgR content was observed. Of pS2-positive patients, 52% had a partial or complete response to hormonal therapy. In 24% of pS2-positive patients the disease stabilized with treatment. In contrast, 27% of pS2-negative patients had a partial or complete response. In 10% of these patients the disease stabilized. Similar associations between therapeutic response and ER or PgR were not observed. The odds of having a clinical response to hormonal therapy was greater for pS2-positive than for ER- or PgR-positive tumors. pS2 expression may define a subset of ER-positive tumors that are more likely to respond to hormonal treatment.


Subject(s)
Biomarkers, Tumor/analysis , Breast Neoplasms/therapy , Fluoxymesterone/therapeutic use , Neoplasm Proteins/analysis , Proteins , Tamoxifen/therapeutic use , Breast Neoplasms/chemistry , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Female , Humans , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasm Proteins/biosynthesis , Neoplasm Staging , Prognosis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Trefoil Factor-1 , Tumor Suppressor Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...